The Journal of Practical Medicine ›› 2026, Vol. 42 ›› Issue (10): 1849-1857.doi: 10.3969/j.issn.1006-5725.2026.10.020

• Treatise: Clinical Practice • Previous Articles    

Mechanism of maresin1 in alleviating lower limb ischemia-reperfusion injury by inhibiting pyroptosis via the TLR4/NF-κB/NLRP3 pathway

Jun LÜ1,Tang DENG1,Jin PENG2,Xunkai WANG1,Jiangpeng WU1,Guiyun JIN1()   

  1. 1.Key Laboratory of Emergency and Trauma of Ministryof Education,Department of Interventional Radiology and Vascular Surgery,the First Affiliated Hospital,Hainan Medical University,Haikou 570000,Hainan,China
    2.Department of Radiology,Hainan Modern Women and Children's Hospital,Haikou 570311,Hainan,China
  • Received:2026-01-19 Online:2026-05-25 Published:2026-05-27
  • Contact: Guiyun JIN E-mail:13976609625@163.com

Abstract:

Objective To investigate the mechanism by which Maresin1 reduces lower limb ischemia-reperfusion injury through the inhibition of pyroptosis. Methods This study employed a combination of in vivo and in vitro experiments. In the in vivo experiment, 27 C57BL/6 mice were randomly allocated into the Control group, the model group (LL-IRI), and the treatment group (MaR1). After successful modeling and drug intervention, the gastrocnemius muscle tissue of 5 mice (n = 5) from each group was collected for transcriptome sequencing and bioinformatics analysis. The remaining samples were utilized to assess histopathological damage and to detect the expression of TLR4/NF-κB p65 and NLRP3/GSDMD proteins. The MDA content and CAT activity in the serum were determined using kits. In vitro, L6 skeletal muscle cells were stimulated with LPS and ATP to establish a pyroptosis model. After modeling, ELISA was applied to measure the content of IL-1β and IL-18 in the supernatant of each group. Results Bulk RNA sequencing analysis demonstrated that, in comparison with the control group, the TLR4/NF-κB/NLRP3 signaling pathway and the expression of pyroptosis-related genes were significantly up-regulated in the LL-IRI group. Moreover, the intervention of MaR1 could reverse the above-mentioned trend, as MaR1 negatively regulated the activation of inflammasomes and the biological process associated with pyroptosis. Immunohistochemistry indicated that the expression of TLR4/NF-κB p65 and NLRP3/GSDMD was significantly enhanced in the LL-IRI group (P < 0.01), accompanied by an increase in serum MDA content (P < 0.01) and a decrease in CAT activity (P < 0.01). MaR1 treatment could significantly improve these pathological, molecular, and biochemical parameters. The results of in vitro experiments showed that, compared with the normal group, there was a significant increase in the release of inflammatory factors IL-1β and IL-18 at the end of pyroptosis in the LPS + ATP group (P < 0.01). After the intervention of MaR1, the release of IL-1β and IL-18 in the LPS + ATP group was significantly reduced (P < 0.01). Conclusion MaR1 may inhibit pyroptosis by blocking the TLR4/NF-κB/NLRP3 inflammatory cascade, thereby alleviating lower limb ischemia/reperfusion (I/R) injury in mice.

Key words: Maresin1, lower limb ischemia-reperfusion injury, pyroptosis, toll-like receptor 4

CLC Number: